BioCentury
ARTICLE | Finance

March 25 Quick Takes: Temasek leads Abbisko’s $70M C round; plus IASO and Regenacy

March 26, 2020 1:26 AM UTC

Abbisko raises $70M series C
Abbisko Therapeutics Co. Ltd. raised $70 million in a series C round, bringing the total funds raised by the cancer company to $140 million since its founding in 2016. Temasek Capital led the round, with participation from existing investors Qiming Venture Partners, Jianxin Capital, GIC, Lilly Asia Ventures, CICC Capital and Loyal Valley Capital.

Hillhouse fund leads IASO’s $60M series B
Nanjing IASO Biotherapeutics raised $60 million in a series B round led by the Hillhouse Capital fund GL Ventures. IASO co-founder and VP of Business Development Brian Hall told BioCentury the company plans to use a significant portion of the funding to support clinical trials in China and IND submission in the U.S. for lead candidate CT103A. It is co-developing the anti-BCMA CAR T therapy with Innovent Biologics Inc. (HKEX:1801) for relapsed or refractory multiple myeloma. The company plans to begin a pivotal Phase II study of CT103A in mid-2020...